期刊文献+

提高创新药研发效率的方法探讨 被引量:3

Doscussion on the ways to increase the efficiency in research and development of investigational new drugs
暂未订购
导出
摘要 随着国内经济水平和科研能力的逐步提高,越来越多的国内制药企业开始进行创新药的研发。本文探讨了跨国制药企业提高创新药研发效率的方法,力求为我国的创新药研发企业提供可以借鉴的思路。 With the development of economy and science in our coun-try,more and more local pharmaceutical companies are commencing the research and development of investigational new drugs.This paper is to research the current states and the ways to increase the successful rate of newdrug development in global pharmaceutical companies.Using their experience for reference,we will establish our good thinking in research and development of new drugs.
作者 杨志敏
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2009年第5期467-470,共4页 The Chinese Journal of Clinical Pharmacology
关键词 创新性药物 研发 思路 investigational newdrug research and development pathway
  • 相关文献

参考文献10

  • 1FDA. Frequendy asked questions on patents and exclusivity [ EB/ OL]. http ://www. fda. gov/Drugs/DevelopmentApprovalProcess/ ucm079031, htm 2009 - 02 - 05.
  • 2Rachel C. Lilly's market prospects hang on new drug offerings[ EB/ OL]. http://news, medill, northwestern, edu/chicago/news, aspx? id = 133215,2009 -06 -04.
  • 3Josef HR,William DT. Work group report on:the drug development pipeline [ EB/OL ] . http://www, massinsight, com/docs/DrugDey. pdf,2005 -03.
  • 4Robert WP. A comparison of product development, lifecycle, and approval pathways: Brand "Is generic products[ EB/OL]. https:// secure, pharmacytimes, com./ lessons/200205 -01. asp, 2002 - 05 -01.
  • 5Mark M. Cost of bringing new drugs to market rising rapidly [ J ]. Psychiatric News, 2003 ;38:25.
  • 6Adverse event reporting news. FDA approvals of NMEs lag [ EB/ OL]. http://www, thefreelibrary, com/FDA + approvals + of + NMEs + lag. -a0175019991,2007 - 11 -05.
  • 7Ismail K, John L Nature reviews [ J ]. Drug Discov , 2004 ; 3 : 711 - 715.
  • 8Maria AG, Navjot S, Rodney W. Why drugs fall short in late - stage trials [ EB/OL]. http://www, mckinseyquarterly, com/Why_ drugs_fallshort_in_late - stage_trials_1879,2007 - 01 - 04.
  • 9Kieran FR, Eric S, Philip HW. Modelling and simulation in clinical drug development [ J]. Drug Discov Today,2001 ;6:802 - 806.
  • 10Rifai N, Gillette MA, Cart SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility[ J]. Nat Biotechnol,2006 ;24:971 - 983.

同被引文献26

  • 1陈孝先.技术特性对技术转移的影响初探[J].科技管理研究,2004,24(3):32-34. 被引量:18
  • 2国家食品药品监督管理局.药品注册管理办法:局令第28号[EB/OL].(2007-07-10)[2013-02-10].http://www.sda.gov.cn/WS01/CL0053/24529.html.
  • 3医药经济报.非专利原研药物的尴尬一定义中国原创药[EB/OL].(2007-10-12)[2012-08-22].http://www.chinapharm.com.cn/html/scfx/1192153323671.html.
  • 4章琰.大学技术转移影响因素模型研究[J].科学学与科学技术管理,2007,28(11):43-47. 被引量:22
  • 5ICH Expert Working Group. ICH guidance S7A, Safety pharma- cology studies for human pharmaceuticals [ EB/OL ]. ( 2000 - 07). http://www, fda. gov/downloads/Drugs/GuidanceCompli- anceRegulatorylnformation/Guidances/ucm074959 . pdf.
  • 6ICH Harmonized Tripartite Guideline STB. Nonclinical evaluation of the potential for delayed ventricular repolarization ( QT interval prolongation) by human pharmaceuticals [ EB/OL]. (2005 - 10), http: //www. fda. gov/cder/Guidance/6885 fn. html.
  • 7ICH Harmonized Tripartite Guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmie drugs [ EB/OL]. (2005 -05 - 12 ). http:// www. ich. org/fileadmin/Public _ Web _ Site/ICH _ Products/ Guidelines/Efficacy/E14/E14_Guideline. pdf.
  • 8JOANNE Z, HUIFANG C, YI T, et al. Lessons Learned From Hundreds of Thorough QT Studies[ J]. Ther Inn Reg Sci, 2015, 49(3) : 392 -397.
  • 9国家食品药品监督管理总局药品审评中心.药物安全药理学研究技术指导原则(征求意见稿)[S].2013.
  • 10国家食品药品监督管理总局药品审评中心.药物QT间期延长潜在作用研究非临床研究技术指导原则(征求意见稿)[S].2013.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部